Both pertuzumab and neratinib have been independently shown to further reduce the risk of recurrence in patients with HER2-positive breast cancer treated with chemotherapy and trastuzumab for one year, though the magnitude of benefit is much smaller than the initial benefit gained from targeting HER2 with the addition of trastuzumab [9, 10]. This evidence concerns the gene ERBB2 and breast carcinoma.